ReviewDiabetology & metabolic syndrome2026
The effect of vitamin D supplementation on the liver function in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis of randomized controlled trials.
Review in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmpirical studies examining the impact of vitamin D supplementation on the liver function in non-alcoholic fatty liver (NAFLD) disease patients have yielded incongruous outcomes. In this systematic review and meta-analysis of randomized controlled trials (RCTs), we investigated the effect of vitamin D supplementation on liver enzymes (alanine transaminase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP)) in NAFLD patients.
methodsA systematic literature search was conducted using scientific databases including PubMed/Medline, Embase, Web of Science, Cochrane library and Scopus, through May 2026. The search strategy included terms for the interventions (vitamin D, cholecalciferol, calcitriol) and outcomes (ALT, AST, ALP, and GGT) in NAFLD patients. Weighted/standardized mean differences (WMD, SMD) and 95% CI were analyzed utilizing a random-effects model.
resultsOverall, 16 RCTs met our inclusion criteria. The current meta-analysis demonstrates a significant reduction in ALT (SMD: -0.45; 95% CI: - 0.87 to -0.04; P = 0.032), and ALP (WMD: -12.91 IU/L; 95% CI: - 18.75 to -7.08; P < 0.001). However, analysis of studies indicated a non-significant effect on AST, GGT. Subgroup analysis showed that the effect of vitamin D on AST is more pronounced in studies with a dose ≤ 3500 IU/day, duration > 12 weeks and using cholecalciferol (as opposed to calcitriol).
conclusionThe findings of this study indicate that vitamin D supplementation may be associated with improvements in ALT and ALP levels, while no significant effects were observed for AST and GGT. These results suggest a possible beneficial role of vitamin D in supporting liver function among patients with NAFLD; however, the evidence remains inconclusive. Future studies are needed to investigate the effect of vitamin D on health status in in NAFLD patients. PROSPERO CODE: CRD42024545499.
Indexed as
Identifiers
42443965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.